Premium
The association between androgen receptor splice variant 7 status and prognosis of metastatic castration‐resistant prostate cancer: A systematic review and meta‑analysis
Author(s) -
Zhou Jiatong,
Liu Ranlu
Publication year - 2020
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/and.13642
Subject(s) - medicine , prostate cancer , oncology , chemotherapy , meta analysis , androgen receptor , endocrine system , subgroup analysis , cancer , hormone
Recent studies have found that metastatic castrated‐resistant prostate cancer (mCRPC) with positive androgen receptor splice variant 7 (AR‐V7) may have poor prognosis during endocrine or chemotherapy treatment, but the specific mechanism was still unclear. We had finished literature search in March 2019 from PubMed, Web of Science database, and Embase. The final results were presented in this research. The pooled results showed that AR‐V7 status predicted pooled PSA‐PFS (HR = 4.31, 95% CI: 2.57–7.24, p < .001), rPFS (HR = 2.39, 95% CI: 1.28–4.48, p = .006) and OS (HR = 4.27, 95% CI: 3.22–5.66, p < .001) in mCRPC patients after endocrine or chemotherapy treatment. Subgroup analysis of different treatments revealed that mCRPC patients treated with chemotherapy had significant association between positive AR‐V7 and OS (HR = 2.82, 95% CI: 1.72–4.62, p < .001), and also during endocrine therapy (HR = 4.78, 95% CI: 3.33–6.86, p < .001). Our study demonstrated that AR‐V7‐positive mCRPC patients may have worse prognosis. AR‐V7 may be an independent prognostic factor for endocrine therapy or chemotherapy in patients with mCRPC.